Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-013840
Filing Date
2024-10-29
Accepted
2024-10-29 16:14:07
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20240930x10q.htm   iXBRL 10-Q 2308344
2 EX-10.1 knsa-20240930xex10d1.htm EX-10.1 88071
3 EX-31.1 knsa-20240930xex31d1.htm EX-31.1 11347
4 EX-31.2 knsa-20240930xex31d2.htm EX-31.2 10503
5 EX-32.1 knsa-20240930xex32d1.htm EX-32.1 6314
6 EX-32.2 knsa-20240930xex32d2.htm EX-32.2 6288
  Complete submission text file 0001558370-24-013840.txt   8720982

Data Files

Seq Description Document Type Size
7 EX-101.SCH knsa-20240930.xsd EX-101.SCH 54290
8 EX-101.CAL knsa-20240930_cal.xml EX-101.CAL 52153
9 EX-101.DEF knsa-20240930_def.xml EX-101.DEF 277852
10 EX-101.LAB knsa-20240930_lab.xml EX-101.LAB 474652
11 EX-101.PRE knsa-20240930_pre.xml EX-101.PRE 386998
76 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20240930x10q_htm.xml XML 1419438
Mailing Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ
Business Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ 7814319100
Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 241405882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)